ERα+ BCs arising in BRCA1-mutated carriers typically show characteristics of biological and clinical aggressiveness, including a higher tumor grade and higher proliferation rates when compared with ERα+ BC occurring in BRCA1 non-carriers [76]. This evidence concerns the gene BRCA1 and breast cancer.